Developing life-saving therapies for blood cancer patients

Kiadis Pharma is a clinical stage biopharmaceutical company developing innovative and potentially life‑saving therapies for patients with late stage blood cancers and related disorders in need of a transplant, an area of significant unmet medical need.

The Company is currently sponsoring a multi‑center Phase II clinical trial for its lead product ATIR™ and is collaborating with with renowned centers in Europe and North America.








Click to download the Company Fact Sheet which provides a valuable insight into where Kiadis Pharma stands today. It summarizes what the Company's lead product ATIR™ is about, its market potential and the progress that is being made in clinical development.



News Digest



Kiadis Pharma features in Nature’s Biopharma Dealmakers edition of September 2014.

Download article

 



ATIR™ Phase I/II study completed



5‑year follow‑up of patients with high‑risk malignancies from Phase I/II clinical study confirms long‑term safety and efficacy of ATIR™ over a broad dose range.


 

Upcoming Conferences



EPIC Biotech Conference
October 2, 2014 - London, United Kingdom

Advanced Therapies Investor Day
November 13, 2014 - London, United Kingdom